AbbVie (ABBV.US) invests $1.4 billion to acquire the neuroscience technology company Aliada Therapeutics.
AbbVie has agreed to acquire all outstanding shares of Aliada Therapeutics, a biotechnology company focused on neuroscience, for 1.4 billion US dollars in cash.
Sector Update: Health Care Stocks Edge Up Monday Afternoon
Sector Update: Health Care
Top Midday Stories: Boeing Launches Public Offerings; McDonald's Quarter Pounder to Return to Menus This Week
AbbVie Is Buying an Alzheimer's Drug for More Than $1 Billion
Sweetgreen, Tesla, Digital Realty Trust And A Health Care Stock On CNBC's 'Final Trades'